Predict your next investment

HEALTHCARE | Biotechnology
adagiotx.com

See what CB Insights has to offer

Founded Year

2020

Stage

IPO | IPO

Total Raised

$466M

Date of IPO

8/6/2021

About Adagio Therapeutics

Adagio Therapeutics (NASDAQ: ADGI) develops antibodies that can broadly neutralize SARS-CoV-2, SARS-CoV-1, and additional potentially emergent coronaviruses.

Adagio Therapeutics Headquarter Location

303 Wyman Street Suite 300

Waltham, Massachusetts, 02451,

United States

781-819-0080

Latest Adagio Therapeutics News

Adagio’s ADG20 demonstrates benefit in Covid-19 clinical programme

Sep 30, 2021

30 Sep 2021 (Last Updated September 30th, 2021 11:40) The company intends to submit the latest data that could support a EUA application in the first quarter of next year. Share Article Adagio Therapeutics has reported that its ADG20 monoclonal antibody demonstrated benefits in its Covid-19 clinical programme. ADG20 acts on the spike protein of SARS-CoV-2 and related coronaviruses and is being developed to prevent and treat Covid-19. Updated six-month results from the company’s ongoing Phase I clinical trial in healthy subjects confirmed the prolonged half-life of ADG20. Furthermore, the company reported data that validated the selection of the 300mg single intramuscular (IM) dose of the antibody being analysed in international Phase II/III STAMP and EVADE trials, which are underway. The Phase I randomised, double-blind, placebo-controlled single ascending dose trial is analysing the safety and tolerability, pharmacokinetics (PK), immunogenicity and serum virus neutralising activity of ADG20 ex vivo against SARS-CoV-2. Nearly, 50% serum virus neutralisation titers observed at six months on administering a 300mg IM dose of ADG20 were in line with reported titers with the mRNA-1273 vaccine. In addition, the titers with ADG20 surpassed those attained with the AZD1222 vaccine series, Adagio noted. ADG20 was well tolerated without any study drug-related adverse events (AEs), serious AEs, or injection-site or hypersensitivity reactions observed through at least three months follow-up across all groups. Subjects will be followed up through one year to evaluate the safety and tolerability, PK, immunogenicity and serum virus-neutralising activity. Data reported so far from the STAMP treatment trial indicate that the 300mg IM regimen could aid in quickly achieving and maintaining target concentrations at vital tissue sites of viral replication. The  EVADE prevention trial data obtained so far showed that a 300mg IM dose of ADG20 has a projected ability to quickly surpass the target serum concentrations in most of the simulated patients. It could also aid in retaining potentially efficient concentrations for up to one year. Adagio chief medical officer Lynn Connolly said: “The continued strength of the safety and pharmacokinetic data from our Phase I study is encouraging and further underscores the potential impact an antibody such as ADG20 – which was designed to be potent, broadly neutralising and delivered as a single IM injection – could have on people with or at risk of Covid-19. “This Phase I data, combined with our dose selection strategy, which relied on our innovative modelling approach, have allowed us to initiate and advance our pivotal trials of ADG20 in the treatment and prevention of Covid-19.” The company noted that these data could support an emergency use authorization (EUA) application in the first quarter of next year. Related Companies

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Adagio Therapeutics

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Adagio Therapeutics in 1 CB Insights research brief, most recently on Aug 5, 2021.

Expert Collections containing Adagio Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Adagio Therapeutics is included in 2 Expert Collections, including Infectious Disease.

I

Infectious Disease

2,226 items

Entities aiding the surveillance, screening, prevention, diagnosis, treatment, and containment of infections & the maintenance of public wellbeing during outbreaks.

B

Biopharmaceuticals

14,138 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Adagio Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Adagio Therapeutics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.